TG Therapeutics Bilanço Sağlığı
Finansal Sağlık kriter kontrolleri 6/6
TG Therapeutics has a total shareholder equity of $177.6M and total debt of $102.9M, which brings its debt-to-equity ratio to 58%. Its total assets and total liabilities are $401.2M and $223.6M respectively. TG Therapeutics's EBIT is $101.8M making its interest coverage ratio 8.2. It has cash and short-term investments of $217.3M.
Anahtar bilgiler
58.0%
Borç/özkaynak oranı
US$102.92m
Borç
| Faiz karşılama oranı | 8.2x |
| Nakit | US$217.25m |
| Eşitlik | US$177.57m |
| Toplam yükümlülükler | US$223.64m |
| Toplam varlıklar | US$401.21m |
Son finansal sağlık güncellemeleri
TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02
TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02Recent updates
TG Therapeutics, Inc.'s (NASDAQ:TGTX) Shares Bounce 27% But Its Business Still Trails The Industry
Sep 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Aug 09TG Therapeutics Delivers A Beat-And-Raise Q2 And A $100 Million Buyback
Aug 07TG Therapeutics (NASDAQ:TGTX) Has A Pretty Healthy Balance Sheet
Aug 02Hold TG Therapeutics For Intriguing Outcomes
Jun 12TG Therapeutics, Inc. (NASDAQ:TGTX) Surges 25% Yet Its Low P/S Is No Reason For Excitement
May 29TG Therapeutics, Inc. (NASDAQ:TGTX) Just Reported First-Quarter Earnings And Analysts Are Lifting Their Estimates
May 04TG Therapeutics: Less Room For Doubt About Briumvi
May 03News Flash: Analysts Just Made A Meaningful Upgrade To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
May 03TG Therapeutics (NASDAQ:TGTX) Has A Somewhat Strained Balance Sheet
Mar 25TG Therapeutics: Briumvi Growth Story Appears Intact
Mar 01Results: TG Therapeutics, Inc. Exceeded Expectations And The Consensus Has Updated Its Estimates
Mar 01TG Therapeutics Made A Strong Impression At The J.P. Morgan Healthcare Conference
Jan 10Some Confidence Is Lacking In TG Therapeutics, Inc.'s (NASDAQ:TGTX) P/S
Jan 04Does TG Therapeutics (NASDAQ:TGTX) Have A Healthy Balance Sheet?
Nov 24TG Therapeutics, Inc. (NASDAQ:TGTX) Not Flying Under The Radar
Sep 30Upgrade: Analysts Just Made A Stunning Increase To Their TG Therapeutics, Inc. (NASDAQ:TGTX) Forecasts
Aug 03Is TG Therapeutics (NASDAQ:TGTX) A Risky Investment?
Jul 19Is TG Therapeutics (NASDAQ:TGTX) Using Debt In A Risky Way?
Apr 13Is TG Therapeutics (NASDAQ:TGTX) Weighed On By Its Debt Load?
Jan 02TG Therapeutics: Elucidating The Upcoming Binary
Oct 09TG Therapeutics: We Are Just Hanging In There
Sep 21Despite Lacking Profits TG Therapeutics (NASDAQ:TGTX) Seems To Be On Top Of Its Debt
Sep 07TG Therapeutics announces peer-reviewed publication of multiple sclerosis phase 3 trials
Aug 25TG Therapeutics Q2 2022 Earnings Preview
Aug 05Finansal Durum Analizi
Kısa Vadeli Yükümlülükler: TGTX's short term assets ($389.2M) exceed its short term liabilities ($108.7M).
Uzun Vadeli Yükümlülükler: TGTX's short term assets ($389.2M) exceed its long term liabilities ($115.0M).
Borç-Özkaynak Tarihçesi ve Analizi
Borç Seviyesi: TGTX has more cash than its total debt.
Borcun Azaltılması: TGTX's debt to equity ratio has reduced from 217% to 58% over the past 5 years.
Borç Kapsamı: TGTX's debt is well covered by operating cash flow (65.9%).
Faiz Kapsamı: TGTX's interest payments on its debt are well covered by EBIT (8.2x coverage).